Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wall

Showing results (121-130 of 200) with videos related to

Pageof 20
Sort By:
Eye and Brain|October 7, 2025
Acetazolamide for Idiopathic Intracranial Hypertension: An Up-to-Date Review in 2025Jaffer Naqvi, Michael Wall, Sophia M Chung, et al.
American Journal of Ophthalmology|January 21, 2017
The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12Michael Wall, Mark J Kupersmith, Matthew J Thurtell, et al.
Allergy and Asthma Proceedings|January 19, 2008
Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitisCarol J Fairchild, Eli O Meltzer, Peter S Roland, et al.
Journal of Environmental Radioactivity|March 14, 2007
Elevated concentrations of primordial radionuclides in sediments from the Reedy River and surrounding creeks in Simpsonville, South CarolinaBrian A Powell, Lara D Hughes, Aurelie M Soreefan, et al.
Journal of Neurology|July 11, 2015
CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment TrialJorge C Kattah, John H Pula, Luis J Mejico, et al.
Obesity Science & Practice|October 27, 2017
A 6-month telephone-based weight loss intervention in overweight and obese subjects with idiopathic intracranial hypertensionRichard Weil, Betty Kovacs, Neil Miller, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 17, 2008
Total deviation probability plots for stimulus size v perimetry: a comparison with size III stimuliMichael Wall, Caridad F Brito, Kimberly R Woodward, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|November 21, 2015
Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment TrialMartin W ten Hove, Deborah I Friedman, Anil D Patel, et al.
Investigative Ophthalmology & Visual Science|March 3, 2016
Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)Michael Wall, Chris A Johnson, Kimberly E Cello, et al.
Neurology|May 22, 2015
Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial resultsKathleen B Digre, Beau B Bruce, Michael P McDermott, et al.
Pageof 20

Showing results (121-130 of 200) with videos related to

Sort By:
Pageof 20
Eye and Brain|October 7, 2025
Acetazolamide for Idiopathic Intracranial Hypertension: An Up-to-Date Review in 2025Jaffer Naqvi, Michael Wall, Sophia M Chung, et al.
American Journal of Ophthalmology|January 21, 2017
The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12Michael Wall, Mark J Kupersmith, Matthew J Thurtell, et al.
Allergy and Asthma Proceedings|January 19, 2008
Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitisCarol J Fairchild, Eli O Meltzer, Peter S Roland, et al.
Journal of Environmental Radioactivity|March 14, 2007
Elevated concentrations of primordial radionuclides in sediments from the Reedy River and surrounding creeks in Simpsonville, South CarolinaBrian A Powell, Lara D Hughes, Aurelie M Soreefan, et al.
Journal of Neurology|July 11, 2015
CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment TrialJorge C Kattah, John H Pula, Luis J Mejico, et al.
Obesity Science & Practice|October 27, 2017
A 6-month telephone-based weight loss intervention in overweight and obese subjects with idiopathic intracranial hypertensionRichard Weil, Betty Kovacs, Neil Miller, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 17, 2008
Total deviation probability plots for stimulus size v perimetry: a comparison with size III stimuliMichael Wall, Caridad F Brito, Kimberly R Woodward, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|November 21, 2015
Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment TrialMartin W ten Hove, Deborah I Friedman, Anil D Patel, et al.
Investigative Ophthalmology & Visual Science|March 3, 2016
Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)Michael Wall, Chris A Johnson, Kimberly E Cello, et al.
Neurology|May 22, 2015
Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial resultsKathleen B Digre, Beau B Bruce, Michael P McDermott, et al.
Pageof 20